Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Hu19-CD828Z T cells |
| Trade Name | |
| Synonyms | HuCD19 anti-CD19 CAR-T cells |
| Drug Descriptions |
Hu19-CD828Z T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD19, and contains CD8alpha hinge and transmembrane domains, a CD28 costimulatory domain, and a CD3 activation domain, which may induce antitumor activity (PMID: 31959992). |
| DrugClasses | CD19 Immune Cell Therapy 72 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Hu19-CD828Z T cells | Hu19-CD828Z T cells | 0 | 0 |
| Hu19-CD828Z T cells + Rituximab | Hu19-CD828Z T cells Rituximab | 0 | 1 |